Tirzepatide 'shot day' videos: what the hype leaves out

What did @itsmamacookie actually say?

She showed herself self-injecting what she calls "trisectile" (tirzepatide) at 12.5 mg, sourced through a telehealth service called MRSMD that ships compounded medication to her door. She says she's not paid to promote them. Her actual advice: get protein, drink water, take electrolytes, and eat right, because "the shot is a tool. It's not going to do all the work for you."

The video is informal, colorful, and genuinely personal. She's not making specific medical claims or promising outcomes. She's documenting a routine and giving lifestyle advice alongside it. That context matters when evaluating accuracy.

One thing worth flagging: she calls the medication "trisectile," which isn't a real drug name. She likely means tirzepatide, the active ingredient in brand-name Mounjaro and Zepbound, also compounded by telehealth pharmacies. That's a small linguistic slip, not a medical error.

Does the science back this up?

Her lifestyle advice is actually well-supported. The claim that tirzepatide is a tool, not a complete solution, is consistent with every major clinical trial. In the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), participants on tirzepatide also followed a reduced-calorie diet and increased physical activity. The drug alone was not the protocol.

Protein intake during GLP-1 therapy is a legitimate concern. Studies have shown that significant weight loss on GLP-1 receptor agonists can include lean mass loss. Research published by Wharton et al. (2023, Obesity) suggested that adequate dietary protein and resistance exercise may help preserve muscle during rapid weight loss on these agents. Her advice to "make sure you get some protein in every day" aligns with what dietitians actually recommend for people on this class of drug.

Electrolytes are also reasonable. Reduced food intake lowers dietary sodium, potassium, and magnesium, and increased hydration (which she also recommends) can dilute electrolytes further. There's no large RCT specifically on electrolytes during GLP-1 therapy, but the physiology supports the advice.

What did they get wrong (or right)?

She got the lifestyle advice right. That's not a small thing. A lot of GLP-1 content on TikTok treats these medications as passive fixes. Her framing is more accurate than most.

What she doesn't address, and what viewers should know, is that 12.5 mg is a maintenance or escalation dose of tirzepatide, not a starting dose. Brand-name Zepbound starts at 2.5 mg and titrates upward over months. Viewers seeing "12.5 mg" without context might assume that's a starting point, which it is not.

She also doesn't distinguish between compounded tirzepatide and FDA-approved brand-name tirzepatide. These are not the same product. Compounded versions are not FDA-approved, not tested for bioequivalence, and their availability has been subject to regulatory change. The FDA removed tirzepatide from its drug shortage list in late 2024, which has significant implications for legal compounding. She's not obligated to explain pharmaceutical regulation in a TikTok, but viewers following her path should be aware of this.

Her claim that she doesn't get paid to tag MRSMD is unverifiable. It may be true. But telehealth companies do pay creators, and undisclosed partnerships are a documented problem on social media health content (FTC, 2023 guidelines update).

What should you actually know?

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It's not just a "GLP-1 shot" as it's often called in shorthand. The dual mechanism is part of why it produced greater average weight loss than semaglutide in the SURMOUNT-5 trial (Jastreboff et al., 2025, NEJM), though head-to-head comparisons are still limited.

Self-injection from a telehealth service is legal and common, but the oversight structure varies widely. A legitimate telehealth provider requires an actual clinical evaluation before prescribing. Patients should verify that their provider includes a licensed prescriber, not just a pharmacy dispatch service.

• Compounded tirzepatide is not FDA-approved and may vary in concentration and purity between compounding pharmacies.
• 12.5 mg is not a starting dose. Jumping to that level without titration increases the risk of nausea, vomiting, and pancreatitis.
• The lifestyle advice in this video (protein, water, electrolytes, eating well) is consistent with clinical recommendations from obesity medicine specialists.
• Injection technique matters. Rotating sites and following sterile procedure reduces lipodystrophy and infection risk.

Bottom line: this video is more responsible than the average GLP-1 TikTok. The lifestyle framing is accurate. The gaps are around dose context, compounding regulation, and disclosure. Those gaps are worth filling in before you order from your phone.